Navigation Links
Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
Date:5/9/2011

SAN DIEGO, May 9, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter of 2011.  For the three months ended March 31, 2011, Orexigen reported a net loss of $11.6 million, or $0.24 per share, as compared to a net loss of $14.1 million, or $0.30 per share, for the first quarter of 2010.  As of March 31, 2011, Orexigen had $39.6 million in cash and cash equivalents and an additional $36.9 million in marketable securities, for a total of approximately $76.6 million.

"Over the last several months, together with our partner, Takeda, and our external advisors, we have been preparing for a meeting with FDA to discuss a viable path forward for Contrave®," said Michael Narachi, president and CEO of Orexigen. "We have submitted to the Agency a specific, innovative, and robust proposal to assess cardiovascular risk and have confirmed a meeting with the Agency later this quarter to discuss our proposal."

Total operating expenses for the first quarter of 2011 were $13.3 million compared to $14.0 million for the first quarter of 2010. This decrease in operating expenses primarily reflects a decrease in research and development expenses of $1.4 million principally related to the reduction in costs incurred in connection with the preparation for our NDA filing for Contrave in the first quarter of 2011 as compared to same period in 2010. This overall decrease was partially offset by an increase in general and administrative expenses principally related to one-time corporate realignment costs.

Conference Call Today at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) The Orexigen management team will host a teleconference and webcast to discuss the first quarter 2011 financial results and recent business highlights. The l
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
2. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
3. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
4. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
5. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
6. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
7. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
8. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
9. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
10. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
11. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Millar, Inc. , a leader in catheter-based and wireless ... Craig Thummel , President/CEO and member of the ... the Company. The Company also announced its leadership succession ... Management team as his successors. The Board of Directors ... Sales and Marketing, as President, and also a member ...
(Date:6/30/2015)... CENTER VALLEY, Pa. , June 30, 2015 ... designing and delivering innovative solutions for medical and ... it is guaranteeing next-day replacements for surgical equipment ... surgical product manufacturer to offer this type of ... an Olympus Full Service Agreement earlier this year. ...
(Date:6/30/2015)... , June 30, 2015  Ardelyx, Inc. (NASDAQ: ... gastrointestinal and metabolic diseases, today announced that the Company ... 2015, from 8:00 a.m.- 1:00 pm EDT in ... The Ardelyx senior management team will present an overview ... tenapanor, which has completed Phase 2b clinical trials for ...
Breaking Medicine Technology:Millar, Inc. Announces Leadership Changes 2Millar, Inc. Announces Leadership Changes 3Olympus Introduces Industry-First Next-Day Product Replacement Guarantee for Surgical Business 2Olympus Introduces Industry-First Next-Day Product Replacement Guarantee for Surgical Business 3Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2
... - Novel, ... 15 Carrington,Laboratories, Inc. (Nasdaq: CARN ) today ... toxicology studies of its,GelVac(TM) nasal powder influenza vaccine, incorporating ... a critical step during the vaccine,development and will assess ...
... N.C., Aug. 16 Cancer patients fraught with,flare-ups ... some assistance,in the form of a new easy-to-use ... to quickly deliver pain medication. Cancer patients ... Persistent cancer pain is characterized as continuous pain,present ...
Cached Medicine Technology:Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine 2Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine 3Novel Technology Breaks Through Cancer Pain 2
(Date:6/30/2015)... Port Richey, FL (PRWEB) , ... June 30, 2015 , ... ... use nearly doubled from 2007 to 2013 while heroin-related deaths more than tripled in ... greatest drug threat (1). Novus Medical Detox Center , a leading Florida-based drug ...
(Date:6/30/2015)... ... 30, 2015 , ... ADVOCATE, the premier provider of radiology ... exclusive billing agreements with Jackson Radiology Associates in Jackson, TN. , ... of billing process software functionality called Experience Based Technology (EBTTM). EBTTM improves ...
(Date:6/30/2015)... ... June 30, 2015 , ... On June 26, 2015, Harper’s ... listed five triggers that most people would not expect to cause acne ... The primary causes of acne are clogged pores and bacteria and each ...
(Date:6/30/2015)... ... June 30, 2015 , ... Lakeview Health, a drug and ... size of its medical staff to further enhance its ability to treat addiction ... practitioners and physician assistants -- now totals 17, compared to 7 in 2013, ...
(Date:6/30/2015)... ... , ... Family and professional dementia caregivers are invited to ... 2015 at the Hyatt Regency Denver Tech Center from 7:30 am-4:30 pm. The ... the wife and daughter of singer Glen Campbell, who will discuss their experiences ...
Breaking Medicine News(10 mins):Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:ADVOCATE Wins Billing Agreements with Jackson Radiology Associates 2Health News:A List of 5 Surprising Acne Triggers and the Latest Acne Treatment Options 2Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2Health News:Family of Singer Glen Campbell to Discuss Living with Dementia at the Alzheimer's Association of Colorado's 26th Annual Education Symposium 2
... a warning in all districts after reports from New Delhi ... the world 30 years ago, along the Bangladesh-Myanmar border. ... said border security agencies have been asked to monitor if ... of the disease. ,Local reports said the alert ...
... new initiative, Coalition for Healthy India (CHI), to improve ... latest treatments and innovation. ,"Access to ... remarkable growth," USIBC President Ron Somers said Thursday while ... of the largest US firms investing in India and ...
... choose to hit beaches during summer in the West, but experts ... it in moderation and with common sense," said Dr. Warren Heymann, ... Camden. ,If you're going to be outside, try to ... appropriate clothing," use sunscreen and reapply it every two to three ...
... large scale clinical trials in order to substantiate preliminary results. ... Inc. were a small scale study which not only looked ... also at its potential as a non-surgical penis enlargement product. ... and development firm, the penis extender was shown to correct ...
... in airports, a man infected with XDR (extensively drug resistant) ... States, underscoring how drug-resistant strains of the disease could be ... attention this story has been receiving over the past few ... the potential nightmare ahead. ,'It's the main reason ...
... CITY, June 1, 2007 (AFP) - The director of ... deaths of more than 100 patients in recent ... after two former directors of the Social Security Fund, ... Thursday in the same case of syrup contaminated with ...
Cached Medicine News:Health News:Small Pox Scare Put West Bengal on High Alert 2Health News:US, India Join Together to Improve Healthcare in India 2Health News:Sunbathers Beware of Skin Cancer, Dermatologists Warn 2Health News:Sunbathers Beware of Skin Cancer, Dermatologists Warn 3Health News:Urologists Begin Clinical Trials on Treatment of Peyronies Disease 2Health News:New Strains of TB Can Be Used as a Powerful Bioterror Weapon 2Health News:New Strains of TB Can Be Used as a Powerful Bioterror Weapon 3
... determines osmolality at room temperature with the ... get are cryoscopic artifacts due to high ... interfere with freezing point determinations. The superbly ... Vapro osmometer has a much broader range ...
Rapid assay, results in 1 hours,Range 20-800 ng/mL; sensitivity 2.5 ng/mL,Can be used for animal sera; requires extraction protocol and steroid free serum...
... IMMULITE 2000 assays are ... the IMMULITE 2000, a ... immunoassay analyzer. IMMULITE 2000 ... centralization, and a rapidly ...
... in specimen radiography. The XPERT represents a research ... of gray in every digital x-ray image, thus ... density that heretofore were lost to the human ... x 2 to 8 x 8 in size, ...
Medicine Products: